ARAF is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is an inclusion eligibility criterion in 12 clinical trials for cutaneous melanoma, of which 10 are open and 2 are closed. Of the trials that contain BRAF status and cutaneous melanoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 2 are phase 3 (2 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GNA11 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

GNAQ is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is an inclusion eligibility criterion in 2 clinical trials for cutaneous melanoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is an inclusion eligibility criterion in 4 clinical trials for cutaneous melanoma, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and cutaneous melanoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [3].

PRKCA is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCA status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCB is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCB status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCD is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCD status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCE is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCE status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCG is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCG status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCI is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCI status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCQ is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCQ status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PRKCZ is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKCZ status and cutaneous melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].